

Vivax malaria resistant to treatment and prophylaxis w

Lancet, The

341, 96-100

DOI: 10.1016/0140-6736(93)92568-e

Citation Report

#	ARTICLE	IF	CITATIONS
1	A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science, 1993, 261, 1182-1184.	12.6	563
2	The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Annals of Tropical Medicine and Parasitology, 1993, 87, 547-552.	1.6	67
3	Diagnosis and treatment of malaria in Britain.. BMJ: British Medical Journal, 1993, 306, 1175-1180.	2.3	50
4	Infectious diseases now. QJM - Monthly Journal of the Association of Physicians, 1993, , .	0.5	0
5	Failure To Detect A Plasmodium vivax-Like Malaria Parasite In Globally Collected Blood Samples. Journal of Infectious Diseases, 1994, 170, 1630-1633.	4.0	22
6	Short-term in vitro culture of Plasmodium vivax and P. ovale for drug-susceptibility testing. Parasitology Research, 1994, 80, 262-264.	1.6	20
7	Blood Stage Antimalarial Efficacy of Primaquine in Plasmodium vivax Malaria. Journal of Infectious Diseases, 1994, 169, 932-935.	4.0	117
8	Malaria vaccine development. Clinical Microbiology Reviews, 1994, 7, 303-310.	13.6	40
9	Drug-Resistant Malaria in Children and in Travelers. Pediatric Clinics of North America, 1995, 42, 649-664.	1.8	20
10	Clinical response and susceptibility in vitro of Plasmodium vivax to the standard regimen of chloroquine in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 426-429.	1.8	32
12	Vivax malaria resistant to chloroquine: case reports from Bombay. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 656-657.	1.8	92
13	Chemotherapy and prevention of drug-resistant malaria. Wilderness and Environmental Medicine, 1995, 6, 307-324.	0.9	20
14	Treatment of Chloroquine-Resistant Plasmodium vivax with Chloroquine and Primaquine or Halofantrine. Journal of Infectious Diseases, 1995, 171, 1678-1682.	4.0	106
15	Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet, The, 1995, 346, 1190-1193.	13.7	136
16	Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria. Parasitology Today, 1996, 12, 399-401.	3.0	267
17	Plasmodium vivax: Merozoites, invasion of reticulocytes and considerations for malaria vaccine development. Parasitology Today, 1996, 12, 20-29.	3.0	138
18	The Treatment of Malaria. New England Journal of Medicine, 1996, 335, 800-806.	27.0	443
19	FALCIPARUM MALARIA. Infectious Disease Clinics of North America, 1996, 10, 747-775.	5.1	53

#	ARTICLE	IF	CITATIONS
20	Pharmacokinetics of Quinine, Chloroquine and Amodiaquine. <i>Clinical Pharmacokinetics</i> , 1996, 30, 263-299.	3.5	257
21	Chemotherapy of Drug-Resistant Malaria. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1996, 7, 25-33.	0.3	11
22	Malaria Prevention by Chloroquine for Seismic Workers in The Tropical Jungle of East Kalimantan, Indonesia. , 1996, , .		0
23	Plasmodium vivax: In Vitro Antiparasitic Effect of Cyclosporins. <i>Experimental Parasitology</i> , 1996, 84, 439-443.	1.2	40
24	Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1996, 90, 409-411.	1.8	75
25	Chloroquine-Resistant Plasmodium vivax Malaria in Borneo. <i>Journal of Travel Medicine</i> , 1996, 3, 124-124.	3.0	10
26	Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1996, 90, 682.	1.8	34
27	Chloroquine sensitive Plasmodium falciparum and P. vivax in central Java, Indonesia. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1996, 90, 412-413.	1.8	9
28	Survey of resistance to chloroquine of falciparum and vivax malaria in Palawan, The Philippines. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1996, 90, 413-414.	1.8	28
29	Failure of Combined Chloroquine and High-Dose Primaquine Therapy for Plasmodium vivax Malaria Acquired in Guyana, South America. <i>Clinical Infectious Diseases</i> , 1996, 23, 1171-1173.	5.8	127
30	Drug resistant Plasmodium vivax malaria. <i>Journal of Antimicrobial Chemotherapy</i> , 1997, 40, 749-752.	3.0	31
31	Studies on a Primaquine-Tolerant Strain of Plasmodium vivax from Brazil in Aotus and Saimiri Monkeys. <i>Journal of Parasitology</i> , 1997, 83, 739.	0.7	31
32	Primaquine-tolerant vivax malaria in Thailand. <i>Annals of Tropical Medicine and Parasitology</i> , 1997, 91, 939-943.	1.6	24
33	MALARIA. <i>Emergency Medicine Clinics of North America</i> , 1997, 15, 113-155.	1.2	19
34	DRUG RESISTANCE AMONG MALARIA AND OTHER PARASITES. <i>Infectious Disease Clinics of North America</i> , 1997, 11, 969-987.	5.1	55
35	Naphthylisoquinoline alkaloids against malaria: evaluation of the curative potentials of dioncophylline C and dioncopeltine A against Plasmodium berghei in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2533-2539.	3.2	122
36	Evaluation of a non-isotopic polymerase chain reaction-based assay to detect and predict treatment failure of Plasmodium vivax malaria in travellers. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 406-409.	1.8	26
37	Malaria diagnosis by the polymerase chain reaction: a field study in southeastern Venezuela. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1998, 92, 509-511.	1.8	43

#	ARTICLE	IF	CITATIONS
38	Survey of resistance in vivo to chloroquine of Plasmodium falciparum and P. vivax in North Sulawesi, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 82-83.	1.8	23
39	Is the malaria diagnosis expensive?. Folia Microbiologica, 1998, 43, 117-119.	2.3	3
40	Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 45-49.	1.8	110
41	Malaria surveillance in New York City: 1991-1996. International Journal of Infectious Diseases, 1998, 2, 132-136.	3.3	21
42	FEVER IN THE RETURNED TRAVELER. Infectious Disease Clinics of North America, 1998, 12, 445-469.	5.1	35
43	Imported Malaria: Prospective Analysis of Problems in Diagnosis and Management. Clinical Infectious Diseases, 1998, 27, 142-149.	5.8	325
44	Drug Resistance in Malaria Parasites of Animals and Man. Advances in Parasitology, 1998, 41, 1-62.	3.2	83
45	Drug resistance in malaria. British Medical Bulletin, 1998, 54, 703-715.	6.9	124
46	Sequence Polymorphism in Two Novel Plasmodium vivax Ookinete Surface Proteins, Pvs25 and Pvs28, That Are Malaria Transmission-blocking Vaccine Candidates. Molecular Medicine, 1998, 4, 772-782.	4.4	108
47	Proteases of Malaria Parasites: New Targets for Chemotherapy. Emerging Infectious Diseases, 1998, 4, 49-57.	4.3	112
48	Adaptation of the AMRU-1 Strain of Plasmodium vivax to Aotus and Saimiri Monkeys and to Four Species of Anopheline Mosquitoes. Journal of Parasitology, 1999, 85, 672.	0.7	14
49	Randomized Dose-Ranging Study of the Safety and Efficacy of WR 238605 (Tafenoquine) in the Prevention of Relapse of Plasmodium vivax Malaria in Thailand. Journal of Infectious Diseases, 1999, 180, 1282-1287.	4.0	91
50	Malaria Prophylaxis Using Azithromycin: A Double-Blind, Placebo-Controlled Trial in Irian Jaya, Indonesia. Clinical Infectious Diseases, 1999, 28, 74-81.	5.8	148
51	Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 637-640.	1.8	48
52	Treatment of vivax malaria on the western border of Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 433-438.	1.8	71
54	Chloroquine sensitivity of Plasmodium vivax in Thailand. Annals of Tropical Medicine and Parasitology, 1999, 93, 225-230.	1.6	25
55	In-vivo sensitivity of Plasmodium vivax isolates from Rondônia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. Annals of Tropical Medicine and Parasitology, 2000, 94, 749-758.	1.6	18
56	Distribution of Plasmodium vivax variants (VK210, VK247 and P. vivax-like) in three endemic areas of the Amazon region of Brazil and their correlation with chloroquine treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 377-381.	1.8	49

#	ARTICLE	IF	CITATIONS
57	Plasmodium vivax synonymous substitution frequencies, evolution and population structure deduced from diversity in AMA 1 and MSP 1 genes. <i>Molecular and Biochemical Parasitology</i> , 2000, 108, 53-66.	1.1	97
58	Drug Treatment of Tropical Parasitic Infections. <i>Drugs</i> , 2000, 60, 985-995.	10.9	34
59	Evidence for Different Mechanisms of Chloroquine Resistance in 2 Plasmodium Species That Cause Human Malaria. <i>Journal of Infectious Diseases</i> , 2001, 183, 1653-1661.	4.0	175
62	Plasmodium vivax Polymorphism in a Clinical Drug Trial. <i>Vaccine Journal</i> , 2001, 8, 891-894.	2.6	45
63	Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13137-13141.	7.1	79
64	Randomized, Placebo-Controlled Trial of Atovaquone/Proguanil for the Prevention of Plasmodium falciparum or Plasmodium vivax Malaria among Migrants to Papua, Indonesia. <i>Clinical Infectious Diseases</i> , 2002, 35, 825-833.	5.8	82
65	Resistance to Antimalarials. <i>Journal of Tropical Pediatrics</i> , 2002, 48, 192-194.	1.5	0
66	An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. <i>Acta Tropica</i> , 2002, 83, 49-61.	2.0	40
67	Malaria: a rising incidence in the United States. <i>Journal of Emergency Medicine</i> , 2002, 23, 23-33.	0.7	14
68	Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3947-3953.	3.2	111
69	Returned Travellers. , 2002, , 185-209.		1
70	Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. <i>Molecular and Biochemical Parasitology</i> , 2002, 119, 63-73.	1.1	70
71	Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam*. <i>Tropical Medicine and International Health</i> , 2002, 7, 858-864.	2.3	77
72	Can primaquine therapy for vivax malaria be improved?. <i>Trends in Parasitology</i> , 2003, 19, 115-120.	3.3	148
74	Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys. <i>Acta Tropica</i> , 2003, 86, 35-40.	2.0	24
75	Preparing the traveller. <i>Lancet, The</i> , 2003, 361, 1368-1381.	13.7	76
77	Novel Point Mutations in the Dihydrofolate Reductase Gene of Plasmodium vivax : Evidence for Sequential Selection by Drug Pressure. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1514-1521.	3.2	124
78	Perspective in Antimalarial Chemotherapy. <i>Current Medicinal Chemistry</i> , 2003, 10, 1137-1150.	2.4	77

#	ARTICLE	IF	CITATIONS
79	Assessment of chloroquine single dose treatment of malaria due to Plasmodium vivax in Brazilian Amazon. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2003, 45, 327-331.	1.1	5
80	Drug-resistant Malaria. , 2004, , 335-360.		0
81	Randomized Trial of 3-Dose Regimens of Tafenoquine (WR238605) versus Low-Dose Primaquine for Preventing Plasmodium vivax Malaria Relapse. Clinical Infectious Diseases, 2004, 39, 1095-1103.	5.8	93
82	Protective T Cell Immunity against Malaria Liver Stage after Vaccination with Live Sporozoites under Chloroquine Treatment. Journal of Immunology, 2004, 172, 2487-2495.	0.8	204
83	Chloroquine Resistance in Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2004, 48, 4075-4083.	3.2	300
84	Primaquine Therapy for Malaria. Clinical Infectious Diseases, 2004, 39, 1336-1345.	5.8	369
85	Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Tropica, 2004, 89, 351-356.	2.0	74
86	Prevention and treatment of malaria in young African children. Seminars in Pediatric Infectious Diseases, 2004, 15, 169-180.	1.7	17
88	Model of the TBP-TFIIB Complex from Plasmodium falciparum: Interface Analysis and Perspectives as a New Target for Antimalarial Design. Archives of Medical Research, 2005, 36, 317-330.	3.3	7
89	Pathogenesis and Management of a Late Manifestation of Vivax Malaria after Deployment to Afghanistan: Conclusions for NATO Armed Forces Medical Services. Military Medicine, 2005, 170, 488-491.	0.8	5
90	Current Status of Malaria Control. Current Medicinal Chemistry, 2005, 12, 2643-2659.	2.4	31
91	Chemoprophylaxis and intermittent treatment for preventing malaria in children. , 2005, , CD003756.		8
92	Pediatric malaria in the developing world. Seminars in Pediatric Infectious Diseases, 2005, 16, 105-115.	1.7	9
93	Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malaria Journal, 2005, 4, 20.	2.3	128
94	Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 410-418.	1.8	28
95	Therapeutic efficacy of chloroquine in Plasmodium vivax from areas with different epidemiological patterns in India and their Pvdhfr gene mutation pattern. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 831-837.	1.8	44
97	Mefloquine Is Highly Efficacious against Chloroquine-Resistant Plasmodium vivax Malaria and Plasmodium falciparum Malaria in Papua, Indonesia. Clinical Infectious Diseases, 2006, 42, 1067-1072.	5.8	66
98	Relapses of Plasmodium vivax Infection Usually Result from Activation of Heterologous Hypnozoites. Journal of Infectious Diseases, 2007, 195, 927-933.	4.0	266

#	ARTICLE	IF	CITATIONS
99	Assessment of safety of the major antimalarial drugs. Expert Opinion on Drug Safety, 2007, 6, 505-521.	2.4	17
100	Treatment of Malaria in the United States. JAMA - Journal of the American Medical Association, 2007, 297, 2264.	7.4	199
101	Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 351-359.	1.8	149
102	Plasmodium yoelii: Influence of antimalarial treatment on acquisition of immunity in BALB/c and DBA/2 mice. Experimental Parasitology, 2007, 116, 266-272.	1.2	15
103	Susceptibility to chloroquine, mefloquine and artemisinin of Plasmodium vivax in northwestern Thailand. Wiener Klinische Wochenschrift, 2007, 119, 76-82.	1.9	7
104	Emerging antibiotic resistance in bacteria with special reference to India. Journal of Biosciences, 2008, 33, 593-603.	1.1	84
105	Perceptions and home management practices of malaria in some rural communities in Abeokuta, Nigeria. Travel Medicine and Infectious Disease, 2008, 6, 210-214.	3.0	26
106	Comparative features and outcomes of malaria at a tertiary care hospital in Karachi, Pakistan. International Journal of Infectious Diseases, 2008, 12, 37-42.	3.3	34
107	Plasmodium vivax Resistance to Chloroquine in Madagascar: Clinical Efficacy and Polymorphisms in pvm-dr1 and pvcrt- α Genes. Antimicrobial Agents and Chemotherapy, 2008, 52, 4233-4240.	3.2	98
108	Tratamiento del paludismo pediátrico: Papel de las intervenciones nutricionales. Annales Nestlé (Ed) Tj ETQq1 1 0.784314 rgBT / Over 0.1		
109	Adverse Pregnancy Outcomes in an Area Where Multidrug-Resistant Plasmodium vivax and Plasmodium falciparum Infections Are Endemic. Clinical Infectious Diseases, 2008, 46, 1374-1381.	5.8	131
110	Chemoprophylaxis and intermittent treatment for preventing malaria in children. , 2008, , CD003756.		36
111	Prise en charge du paludisme pédiatrique: rôle des interventions nutritionnelles. Annales Nestlé [Ed Française], 2008, 66, 31-47.	0.0	1
113	Management of Pediatric Malaria: Role of Nutritional Interventions. Annales Nestlé, 2008, 66, 31-47.	0.1	4
114	Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2009, 53, 1468-1475.	3.2	154
115	New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Current Opinion in Infectious Diseases, 2009, 22, 430-435.	3.1	300
116	Biological Resistance of Hydroxychloroquine for Plasmodium vivax Malaria in the Republic of Korea. American Journal of Tropical Medicine and Hygiene, 2009, 81, 600-604.	1.4	24
117	Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malaria Journal, 2009, 8, 177.	2.3	51

#	ARTICLE	IF	CITATIONS
118	Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. <i>Malaria Journal</i> , 2009, 8, 20.	2.3	34
119	Artemisinin combination therapy for vivax malaria. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 405-416.	9.1	204
120	Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu. <i>Malaria Journal</i> , 2010, 9, 89.	2.3	11
121	Malaria Distribution, Prevalence, Drug Resistance and Control in Indonesia. <i>Advances in Parasitology</i> , 2011, 74, 41-175.	3.2	104
123	High genetic polymorphism of relapsing P. vivax isolates in northwest Colombia. <i>Acta Tropica</i> , 2011, 119, 23-29.	2.0	31
124	Phenotyping clinical resistance to chloroquine in Plasmodium vivax in northeastern Papua, Indonesia. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2011, 1, 28-32.	3.4	9
125	Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. <i>Parasites and Vectors</i> , 2011, 4, 46.	2.5	45
126	Plasmodium vivax: Prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan. <i>Experimental Parasitology</i> , 2011, 127, 167-172.	1.2	20
127	Molecular epidemiology of Plasmodium vivax anti-folate resistance in India. <i>Malaria Journal</i> , 2011, 10, 102.	2.3	31
128	Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia. <i>Malaria Journal</i> , 2011, 10, 214.	2.3	27
129	Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. <i>Malaria Journal</i> , 2011, 10, 44.	2.3	21
130	Respuesta terapéutica del Plasmodium vivax a la cloroquina, en Riberalta, Guayaramerín y Yacuiba, Bolivia. <i>Biomedica</i> , 2012, 32, .	0.7	2
131	Antimicrobial Action of Chelating Agents: Repercussions on the Microorganism Development, Virulence and Pathogenesis. <i>Current Medicinal Chemistry</i> , 2012, 19, 2715-2737.	2.4	58
132	Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. <i>The Cochrane Library</i> , 2012, , CD003756.	2.8	100
133	Border Malaria Associated with Multidrug Resistance on Thailand-Myanmar and Thailand-Cambodia Borders: Transmission Dynamic, Vulnerability, and Surveillance. <i>BioMed Research International</i> , 2013, 2013, 1-13.	1.9	72
134	Preparation of Malaria Resurgence in China. <i>Advances in Parasitology</i> , 2014, 86, 205-230.	3.2	20
135	Surveillance of antimalarial drug resistance in China in the 1980s-1990s. <i>Infectious Diseases of Poverty</i> , 2014, 3, 8.	3.7	19
136	Resistance of infection by Plasmodium vivax to chloroquine in Bolivia. <i>Malaria Journal</i> , 2015, 14, 261.	2.3	20

#	ARTICLE	IF	CITATIONS
137	Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate <i>Plasmodium vivax</i> in southern Mexico. <i>Malaria Journal</i> , 2015, 14, 426.	2.3	18
138	<i>Malaria (Plasmodium Species)</i> . , 2015, , 3070-3090.e9.		9
139	Confirmed <i>Plasmodium vivax</i> Resistance to Chloroquine in Central Vietnam. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7411-7419.	3.2	28
140	Therapeutic Responses of <i>Plasmodium vivax</i> Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1230-1235.	3.2	48
141	Evaluation of the paediatric dose of chloroquine in the treatment of <i>Plasmodium vivax</i> malaria. <i>Malaria Journal</i> , 2016, 15, 371.	2.3	8
142	Combating malaria with nanotechnology-based targeted and combinatorial drug delivery strategies. <i>Drug Delivery and Translational Research</i> , 2016, 6, 414-25.	5.8	15
143	Population pharmacokinetics of a three-day chloroquine treatment in patients with <i>Plasmodium vivax</i> infection on the Thai-Myanmar border. <i>Malaria Journal</i> , 2016, 15, 129.	2.3	24
144	Primaquine at alternative dosing schedules for preventing relapse in people with <i>Plasmodium vivax</i> malaria. <i>The Cochrane Library</i> , 0, , .	2.8	2
145	Measuring ex vivo drug susceptibility in <i>Plasmodium vivax</i> isolates from Cambodia. <i>Malaria Journal</i> , 2017, 16, 392.	2.3	18
146	Primaquine double dose for 7 days is inferior to single-dose treatment for 14 days in preventing <i>Plasmodium vivax</i> recurrent episodes in Suriname. <i>Infection and Drug Resistance</i> , 2017, Volume 11, 3-8.	2.7	2
147	Use of Combination Therapy in Malaria Treatment and Prevention in Indonesia. <i>Journal of Pharmaceutical and Sciences</i> , 2021, 4, 29-33.	0.1	0
148	Resistance to Antimalarial Drugs: Parasite and Host Genetic Factors. , 2006, , 81-124.		4
149	<i>Plasmodium Species (Malaria)</i> . , 2010, , 3437-3462.		15
150	<i>Medical Parasitology</i> . , 2011, , 1188-1238.		4
151	In-vivo sensitivity of <i>Plasmodium vivax</i> isolates from Rondônia (western Amazon region, Brazil) to regimens including chloroquine and primaquine. <i>Annals of Tropical Medicine and Parasitology</i> , 2000, 94, 749-758.	1.6	26
152	High-Level Expression of <i>Plasmodium vivax</i> Apical Membrane Antigen 1 (AMA-1) in <i>Pichia pastoris</i> : Strong Immunogenicity in <i>Macaca mulatta</i> Immunized with <i>P. vivax</i> AMA-1 and Adjuvant SBAS2. <i>Infection and Immunity</i> , 1999, 67, 43-49.	2.2	81
153	Therapy with a Combination of Low Doses of Interleukin 12 and Chloroquine Completely Cures Blood-Stage Malaria, Prevents Severe Anemia, and Induces Immunity to Reinfection. <i>Infection and Immunity</i> , 1999, 67, 513-519.	2.2	42
154	Chloroquine Resistant <i>Plasmodium vivax</i> : In Vitro Characterisation and Association with Molecular Polymorphisms. <i>PLoS ONE</i> , 2007, 2, e1089.	2.5	187

#	ARTICLE	IF	CITATIONS
155	Need for Abundant Caution in Prophylactic Application of Chloroquine and Hydroxychloroquine for Viral Infections Including COVID-19: Possibility of Increased Susceptibility. SSRN Electronic Journal, 0, ,	0.4	2
156	Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia.. American Journal of Tropical Medicine and Hygiene, 1998, 59, 513-518.	1.4	82
157	In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.. American Journal of Tropical Medicine and Hygiene, 1999, 60, 542-546.	1.4	20
158	Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.. American Journal of Tropical Medicine and Hygiene, 1999, 61, 973-977.	1.4	45
159	Adaptation of a chloroquine-resistant strain of Plasmodium vivax from Indonesia to New World monkeys.. American Journal of Tropical Medicine and Hygiene, 2000, 62, 491-495.	1.4	18
160	Assessing drug sensitivity of Plasmodium vivax to halofantrine or chloroquine in southern, central Vietnam using an extended 28-day in vivo test and polymerase chain reaction genotyping.. American Journal of Tropical Medicine and Hygiene, 2000, 62, 693-697.	1.4	22
161	Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia.. American Journal of Tropical Medicine and Hygiene, 2001, 64, 223-228.	1.4	47
162	Plasmodium vivax clinically resistant to chloroquine in Colombia.. American Journal of Tropical Medicine and Hygiene, 2001, 65, 90-93.	1.4	105
163	Assessing the Parasight-F test in northeastern Papua, Indonesia, an area of mixed Plasmodium falciparum and Plasmodium vivax transmission.. American Journal of Tropical Medicine and Hygiene, 2002, 66, 649-652.	1.4	9
164	VERY HIGH RISK OF THERAPEUTIC FAILURE WITH CHLOROQUINE FOR UNCOMPLICATED PLASMODIUM FALCIPARUM AND P. VIVAX MALARIA IN INDONESIAN PAPUA. American Journal of Tropical Medicine and Hygiene, 2003, 68, 416-420.	1.4	107
165	CHLOROQUINE-RESISTANT PLASMODIUM VIVAX MALARIA IN PERU. American Journal of Tropical Medicine and Hygiene, 2003, 69, 548-552.	1.4	100
166	Vivax Malaria: Neglected and Not Benign. American Journal of Tropical Medicine and Hygiene, 2007, 77, 79-87.	1.4	675
167	Resistance to Chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in Eastern Indonesia. American Journal of Tropical Medicine and Hygiene, 2009, 81, 338-342.	1.4	28
168	A Regional Centralized Microbiology Service in Calgary for the Rapid Diagnosis of Malaria. Archives of Pathology and Laboratory Medicine, 2003, 127, 687-693.	2.5	5
169	Drug Resistance in Malaria-in a nutshell. Journal of Applied Pharmaceutical Science, 0, , 137-143.	1.0	9
171	Antimalarial drug resistance in the Eastern Mediterranean Region. Eastern Mediterranean Health Journal, 2003, 9, 492-508.	0.8	18
172	Antimalarial Drug Resistance: Clinical Perspectives. , 2009, , 1077-1090.		0
173	Infektionskrankheiten und Schutzimpfungen. , 2011, , 967-1113.		0

#	ARTICLE	IF	CITATIONS
175	Drug Resistance in Malaria. <i>Medicinal Chemistry</i> , 1972, 12, 32-45.	0.1	48
176	Malaria prophylaxis in Indonesia. <i>Medical Journal of Indonesia</i> , 1992, 2, 23-9.	0.5	0
177	Malaria: <i>Plasmodium falciparum</i> (Welch 1898), <i>Plasmodium vivax</i> (Grassi and Filetti 1889), <i>Plasmodium ovale</i> (Stephens 1922), <i>Plasmodium malariae</i> (Laveran 1881). , 1995, , 174-189.		0
180	Effect of Siddharthakadi Agada in the Management of Malaria (Jwara). <i>Environment Conservation Journal</i> , 2018, 19, 31-36.	0.2	0
181	Pharmacology of Antimalarial Drugs, <i>Current Anti-malarials</i> . , 2019, , 1-82.		1
182	<i>Plasmodium vivax</i> Mimicking Morphologic Features of <i>Plasmodium falciparum</i> . <i>Cureus</i> , 2020, 12, e11406.	0.5	1
186	Sequence polymorphism in two novel <i>Plasmodium vivax</i> ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. <i>Molecular Medicine</i> , 1998, 4, 772-82.	4.4	37
187	<i>Vivax malaria</i> : neglected and not benign. <i>American Journal of Tropical Medicine and Hygiene</i> , 2007, 77, 79-87.	1.4	445
188	Antimalarials for children with <i>Plasmodium vivax</i> infection: Current status, challenges, and research priorities. <i>Parasitology International</i> , 2022, 87, 102512.	1.3	7
189	Therapeutic efficacy of chloroquine for uncomplicated <i>Plasmodium vivax</i> malaria in southeastern and western border areas of Myanmar. <i>Infection</i> , 2022, , 1.	4.7	1
190	Circumsporozoite Protein from <i>Plasmodium vivax</i> and its Relationship to Human Malaria. , 0, , .		0
191	How I Manage the Febrile Returning Traveller. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 1998, 28, 24-33.	0.6	0
192	Modern Malaria. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 1998, 28, 370-382.	0.6	13
193	Drug resistance of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> isolates in Indonesia. <i>Malaria Journal</i> , 2022, 21, .	2.3	9
194	A review of malaria molecular markers for drug resistance in <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> in China. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	3.9	0